Entera Bio

Entera Bio EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Entera Bio (ENTX) as of Nov 22, 2026 is -20.28 %. In the previous year, Year-over-Year EBITDA Growth was -7.21 % — a change of 181.11% (lower).

EBITDA Growth YoY

-20.28 %

YoY

181.11%

Last updated:

Year-over-Year EBITDA Growth of Entera Bio is 2025 -20.28 % . Year-over-Year EBITDA Growth of Entera Bio was 2024 -7.21 % . It decreases by 181.11% lower compared to the previous year.

The Entera Bio EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
-195.75 USD
Jan 1, 2019
-5.46 USD
Jan 1, 2020
2.80 USD
Jan 1, 2021
-9.74 USD
Jan 1, 2022
-6.55 USD
Jan 1, 2023
31.32 USD
Jan 1, 2024
-7.21 USD
Jan 1, 2025
-20.28 USD
The Entera Bio EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-20.28 %+181.11%
-7.21 %-123.04%
31.32 %-578.30%
-6.55 %-32.75%
-9.74 %-447.43%
2.80 %-151.33%
-5.46 %-97.21%
-195.75 %-162.87%
311.35 %-791.65%
-45.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Year-over-Year EBITDA Growth of Entera Bio is -20.28 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Entera Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Entera Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Entera Bio

All Key Metrics — Entera Bio